Figure 3
Analyses of tumorigenic potential in miPS-PGE2 cells. (A) Tumor derived from miPS-PGE2 cells in s.c. (left) and excised (right). Scale bar 5 mm. (B) Time course change of the tumor size. Data are plotted by means + SD. **p < 0.05 (C) Representative images from two different field of miPSCs derived teratoma after four weeks of injection as a control showing a phenotype with various normal germ layers, including squamous epithelium, skeletal muscle, cartilage, and benign glandular epithelium. (D) Representative images of miPS-PGE2 derived malignant tumor after four weeks of injection (C,D) H&E staining. I, low magnification. II, maginification of the part squared in I. III and IV, Different fields of the section. Asterisks in II and IV depict severe nuclear atypia. Black arrows in II and IV depict mild nuclear atypia. Black arrow in III depicts invasion. White arrow in IV depicts necrosis. Scale bars 307 (top left), 64 (top right), 100 (bottom left), 50 (bottom right) µm. (E) Immunohistochemistry of the tumor in A. The tumor was stained with antibodies against E-cadherin, Ki67 and CD44. Sections from miPSC derived teratoma (left column) and those from miPS-PGE2 derived malignant tumor (right column) Scale bars 64 µm. (F) Adhesive culture of miPSCs and the primary cells derived from miPS-LLCcm and miPS-PGE2 cells. BF, bright field. GFP, fluorescence from GFP. Scale bar 100 µm. (G) Comparison of the expression of Stemness marker between miPSCs (a), miPS-LLCcmP cells (b) and miPS-PGE2P cells (c) by RT-qPCR. Data were plotted as means ± SD. *p < 0.1, **p < 0.05, ***p < 0.01. (H) Comparison of the expression of CD44 and CD133 between miPSCs (a), miPS-LLCcmP cells (b) and miPS-PGE2P cells (c) by RT-qPCR. Data are plotted as means ± SD. **p < 0.05, ***p < 0.01.
